If the White House announces a psychedelic research initiative before August 2026, it will be framed around helping veterans with opioid addiction and PTSD, not recreational drug legalization. It will probably mention psilocybin or ibogaine but avoid naming MDMA (the party drug), because that association polls badly across party lines. This framing lets politicians claim interest in psychedelic medicine as helping veterans while avoiding 'rave drug' attacks.
Political coalition math is clear: ibogaine and psilocybin carry less cultural baggage in conservative media than MDMA, which has persistent 'rave drug' associations. Veteran opioid recovery polls strongly across partisan lines and provides a defensible framing for what would otherwise be attacked as drug legalization. The Trump administration has already signaled interest in psychedelics through the DOGE-adjacent wellness framing; the announcement vehicle will need to be politically bulletproof. MDMA's association with Lykos/MAPS and progressive advocacy makes it a liability in this framing.